You are here

Article Text

Article menu
Download PDFPDF
BASHH column
Drospirenone: a new progestogen-only contraception for future use in integrated sexual health services
  1. Rebecca Cannon,
  2. Suzanne Jewell
  1. Department of Genitourinary Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
  1. Correspondence to Dr Rebecca Cannon; rebecca.cannon{at}nhs.net

https://doi.org/10.1136/sextrans-2024-056170

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    BASHH clinicians often work within integrated services, where contraception is also provided. It is therefore advisable to be aware of new developments in this area. The progestogen-only pill (POP), Slynd entered the UK Market in 2022. It contains a different type of progestogen to those currently available; drospirenone. Although drospirenone has been part of a number of combined oral contraceptive pills (COCPs) for some time, this is the first licensed preparation of drospirenone alone. A new POP provides more options for those who cannot take oestrogen-containing contraception but wish to remain on an oral method, or for those who have experienced unwanted side effects with other progestogen-containing methods, including other POPs. Each packet contains 24 active …

    View Full Text

    Footnotes

    • Handling editor Anna Maria Geretti

    • Contributors RC wrote initial manuscript. RC and SJ edited final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.